The Clinical Trial Regulation (Regulation (EU) No 536/2014)* simplifies the application process and increases transparency of clinical trials in the EU. It aims to harmonize the preparation, submission, review of clinical trial applications (CTAs) and the conduct of clinical trials. It applies to all interventional clinical trials regardless of whether conducted in one or several EU Member States.
 
 As of end of January 2022 (EU wide harmonized) CTA dossiers can be submitted via Clinical Trials Information System (CTIS), a new single EU portal/database overseen by the EMA. Submission will be followed by a collaborated assessment conclusion and decision for both Health Authorities (HAs) and Ethic Committees (ECs) within the EU via CTIS. The one-year transition period started on 31 January 2022 and will end on 31 January 2023. During this period, Boehringer will run pilots under the umbrella of the new regulation. The Regulation also defines harmonized criteria for authorization process, safety reporting, labelling requirements and transparency/publication rules throughout the EU.
 
 In this presentation on we share our approach to implement the Clinical Trial Regulation in a structured and pragmatic way within the cross-functional team at Boehringer Ingelheim to efficiently manage and leverage the new opportunities of the harmonized EU process. Corresponding to the presented approach, we will outline lessons learned and future outlook of the efficient management of Clinical Trials under EU CTR.
 
 *https://www.ema.europa.eu/en/human-regulatory/research-development/clinical-trials/clinical-trial-regulation

Strategy on Implementation of EU Clinical Trial Regulation – Lessons learned by the first submissions at Boehringer Ingelheim

For it's 35th anniversary, DIA Europe is back in Basel, where all thought leaders meet in person to discuss, inspire, and network.

Join us in Basel: March 22-24, 2023

DIA Europe 2023 is designed to drive insights into action by connecting key policy discussions to real-world knowledge that you need for your everyday job. Your participation will accelerate your growth and your organization's performance in the drug development ecosystem.

Gathering innovative thought leaders from the entire life science landscape, DIA always has the aspiration to be ahead of current developments, reflected by 4 new content tracks in 2023:

- Artificial Intelligence and Data Science
- EU Health Policy and Regulatory Strategy
- Medical Devices and Combination Products
- Professional Development

DIA Europe 2023

A global, member-driven non-profit organization mobilizing life sciences and healthcare. DIA fosters innovation to improve health and well-being worldwide. Professionals from 80 countries continue to engage with DIA through our unparalleled membership network, educational offerings, and professional development opportunities.